Lipid and Lipoprotein Metabolism in Liver Disease

Mariana Acuña; David E. Cohen

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Feingold KR, Adler RA, Ahmed SF, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-.

Endotext [Internet].

Show details

< Prev Next >

Lipid and Lipoprotein Metabolism in Liver Disease

Mariana Acuña, PhD and David E. Cohen, MD, PhD.

Author Information and Affiliations

Last Update: March 6, 2026.

ABSTRACT

The liver plays a central role in lipid metabolism, serving as the center for lipoprotein uptake, formation, and export to the circulation. Alterations in hepatic lipid metabolism can contribute to the development of chronic liver disease, such as metabolic dysfunction-associated steatotic liver disease (MASLD) and accelerate the progression of other chronic liver diseases, as occurs in hepatitis C. Moreover, chronic liver disease can impact hepatic lipid metabolism, thereby contributing to dyslipidemia. This chapter discusses the interplay between lipid metabolism and common chronic liver diseases, as well as cirrhosis. For complete coverage of all related areas of Endocrinology, please visit our on-line FREE web-text, WWW.ENDOTEXT.ORG.

METABOLIC-DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE

Case Presentation

A 60-year-old woman with a past medical history significant for hypertension, dyslipidemia, and diabetes mellitus presents for management of newly diagnosed metabolic dysfunction-associated steatohepatitis (MASH). She has a strong family history of coronary artery disease and a personal history of dyslipidemia characterized by a serum triglyceride level of 220 mg/dL, low-density lipoprotein (LDL) cholesterol of 180 mg/dL, high-density lipoprotein (HDL) cholesterol of 50 mg/dL and total cholesterol of 274 mg/dL. Based on these values, her primary physician has recommended she start a lipid-lowering medication. However, with her history of liver disease she is uncertain whether she can safely take lipid-lowering medications.

Introduction

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly called nonalcoholic fatty liver disease (1, 2), is the most common cause of chronic liver disease in the United States, affecting up to a third of adults (3-5). MASH is the inflammatory and fibrotic form of MASLD and can progress to cirrhosis and hepatocellular carcinoma. In addition to significant morbidity and mortality from end-stage liver disease, MASLD confers an increased risk of cardiovascular disease (CVD) (6). CVD is the leading cause of mortality among individuals with MASLD (7). The dyslipidemia attributable to MASLD may be one of several important and modifiable CVD risk factors.

Changes in Lipoprotein Metabolism and Clinical Manifestations

DEVELOPMENT OF STEATOSIS

MASLD is characterized in part by steatosis, or excess lipid deposition as lipid droplets within hepatocytes. These lipid droplets consist largely of triglycerides and are the result of an imbalance of hepatic lipid processing (8). Steatosis can occur when one or more of the following conditions are present: 1) excess delivery of free fatty acids (FFA) to the liver from adipose tissue through the plasma, 2) increased de novo lipogenesis (DNL) within the liver, 3) decreased oxidation of fatty acids within hepatocytes and 4) impaired export of triglycerides from the liver in the form of very-low-density lipoproteins (VLDL).

Excess FFA Delivery to the Liver

In the setting of excess adiposity and insulin resistance, FFA release from adipocytes is increased (9). Upon release, FFA are then delivered via the circulation to the liver and may exceed the liver’s capacity to oxidize or export lipids, contributing to the development of steatosis. The fatty acid translocase FAT/CD36 mediates uptake of FFA into the liver and is upregulated in human and experimental MASLD, which may contribute to steatosis (10-12).

Increased DNL

Hyperinsulinemia, often observed in the setting of obesity and the metabolic syndrome, can also contribute to excess DNL as the result of increased transcriptional activities of sterol regulatory element binding protein (SREBP) 1c- and peroxisome proliferator-activated receptor (PPAR)-γ (9, 13, 14). Increased circulating glucose levels also mediate lipogenesis by activating cholesterol regulatory element binding protein (ChREBP) (15). The increased synthesis of lipids within the liver can lead to accumulation within hepatocytes and can promote the development of steatosis.

Insufficient Export of Hepatic Triglycerides

Export of triglycerides from the liver requires the formation of VLDL particles. Steatosis can occur when VLDL formation is insufficient or is impaired. VLDL are formed when triglycerides are complexed to apolipoprotein B100 (apoB100) via the action of microsomal triglyceride transfer protein (MTP). Genetic or pharmacologic alteration of MTP or the truncation or absence of ApoB100 can lead to steatosis (16-20). In addition, ApoB100 levels can be decreased as a result of FFA accumulation. FFA accumulation within the liver can lead to chronic stress of the hepatocyte endoplasmic reticulum (ER). Increased ER stress results in increased ApoB100 degradation, decreasing the ability of the liver to export triglycerides and potentially worsen steatosis.

VLDL assembly and secretion rely on several additional steps. Following the formation of nascent VLDL particles, additional lipidation is needed to create mature VLDL particles. The process of lipidation is not well understood but may rely on fusion with lipid droplets (21). Interruption of lipid mobilization from lipid droplets to VLDL may also contribute to the development of steatosis (22). Genetic studies have demonstrated a strong link between a polymorphism in the gene patatin-like phospholipase domain-containing 3 (PNPLA3) and MASLD. This coding region polymorphism (I148M) reduces hepatic VLDL secretion, possibly by interfering with triglyceride mobilization, and results in hepatic steatosis (23-25). However, conflicting data suggest that some patients with MASLD exhibit a compensatory increase in VLDL export, although this response remains insufficient to offset the elevated hepatic triglyceride burden (26). The transmembrane 6 superfamily 2 (TM6SF2) E167K variant results in decreased hepatic VLDL secretion and is associated with MASLD, fibrosis, and cirrhosis in the setting of decreased plasma LDL and triglyceride levels. This variant is associated with progressive liver disease but decreased risk of cardiovascular disease (27, 28). As for TM6SF2 variants, PNPLA3 I148M and ApoB polymorphisms that promote MASLD have been associated with reduced risk of cardiovascular disease, presumably owing to decreased hepatic secretion of ApoB-containing lipoproteins (29, 30). Familial hypobetalipoproteinemia (FHBL) is a condition characterized by diminished levels of functional ApoB100, resulting in impaired VLDL export and the development of hepatic steatosis. Magnetic resonance spectroscopy studies have shown that individuals with FHBL exhibit hepatic fat content approximately fivefold higher than that of controls (31, 32). Progression to steatohepatitis, cirrhosis and hepatocellular carcinoma (HCC) has been noted in these individuals (33-36).

Hepatic Accumulation of Free Cholesterol

The degree of hepatic free cholesterol accumulation in MASLD correlates with the presence and severity of cytologic ballooning (37). Decreased expression of ATP-binding cassette (ABC) A1 and ABCG8 cholesterol efflux proteins, may disrupt transfer of cholesterol from hepatocytes, driving up hepatocyte cholesterol (38, 39). Transcriptional upregulation of the LDL receptor and downregulation of cholesterol conversion to bile acids may further contribute to excess hepatic accumulation (40).

CHANGES IN LIPOPROTEINS

Dyslipidemia is frequent in adults with radiographic and biopsy-proven MASLD and is characterized by hypertriglyceridemia, increased LDL particle concentrations, decreased LDL particle size, and decreased HDL-cholesterol levels (41). High ratios of total cholesterol or triglyceride to HDL-cholesterol are associated with MASLD (42). Recent analyses have revealed that circulating sulfatides redistribute from HDL to LDL and are associated with the hepatic inflammatory pathways implicated in the initiation of fibrosis in MASLD. These bioactive molecules prove clinically useful non-invasive biomarkers capable of predicting mild fibrosis in MASLD (43).

In addition, non-HDL-cholesterol (non-HDL-C), a composite measure of apolipoprotein-B containing lipoproteins and an important marker of CVD risk, is elevated in individuals with MASLD and MASH (44, 45). MASH is also characterized by alterations in lipoprotein subfractions. Lipoprotein subfraction assays measure lipoprotein particle size, density, and composition. MASH is characterized by large VLDL particle size and decreased sizes of LDL and HDL particles (41). However, there are conflicting data on the association between MASH and VLDL particle size (21). Furthermore, increased levels of LDL-III and IV particles, which are more atherogenic LDL fractions, and reduced HDL2b levels, which are cardioprotective, are observed in MASH (42, 46). Fortunately, resolution of MASH is associated with increases in HDL, decreases in triglycerides, and increases in mean both LDL particle diameter and the frequency of the atherogenic LDL phenotype A (47, 48).

A distinct LDL-like particle is formed when the glycoprotein apolipoprotein(a) is covalently linked to apoB-100, resulting in lipoprotein(a) (Lp(a)). Elevated Lp(a) concentrations have been associated with an increased risk of cardiovascular disease, including myocardial infarction (49). The association between Lp(a) and liver disease appears to depend upon the extent of liver disease. In advanced fibrosis and cirrhosis, circulating Lp(a) levels decline, likely reflecting impaired hepatic synthetic capacity (50). Similar patterns have been reported in individuals with type 2 diabetes (51). Considering this, cardiovascular risk may be underestimated if evaluation is limited to Lp(a) without accounting for the presence of advanced liver fibrosis (52).

Table 1.

Alterations in Plasma Lipids and Lipoprotein in the setting of Metabolic Dysfunction Associated Liver Disease (MASLD) and Metabolic Dysfunction Associated Steatohepatitis (MASH)

	MASLD	MASH
Plasma triglycerides	↑	↑
VLDL production*/particles	↑	↑↑
LDL size	↓	↓↓
LDL cholesterol	↑	↑
HDL cholesterol	↓	↓↓
Non-HDL cholesterol	↑	↑
Lp(a)	Typically unaffected	↓ with increasing fibrosis

*: Excluding the presence of genetic polymorphisms that decrease hepatic VLDL secretion.

Insulin Resistance

Insulin resistance is an underpinning of MASLD and contributes to the pathogenesis of the associated dyslipidemia.

INSULIN RESISTANCE INCREASES CIRCULATING LDL, VLDL, AND TRIGLYCERIDE LEVELS

Apart from increasing FFA delivery to the liver and stimulating DNL, insulin resistance can increase circulating VLDL and plasma triglyceride concentrations through several mechanisms. First, insulin resistance leads to a loss of suppression of MTP transcription, increasing the efficiency of VLDL assembly (53, 54). In addition, insulin resistance reduces the expression of lipoprotein lipase (LPL) that is bound to endothelial cells within muscle and adipose tissue. LPL hydrolyzes triglycerides from circulating VLDL and thereby facilitates fatty acid delivery to muscle and adipose tissues. As a result, impaired VLDL clearance due to LPL downregulation results in increased plasma triglyceride concentrations (55).

Insulin resistance can also increase circulating levels of ApoCIII, an apolipoprotein that binds to VLDL and inhibits LPL activity, thereby further reducing VLDL clearance from the circulation (56). Notably, ApoCIII also appears to modulate plasma triglyceride levels by LPL-independent mechanisms. In patients with LPL deficiency due to familial chylomicronemia syndrome, administration of an ApoCIII mRNA inhibitor for 13 weeks reduced plasma triglycerides by 56-86% (57).

Insulin resistance also impacts LDL metabolism by upregulating hepatic lipase and increasing LDL receptor degradation. Hepatic lipase is an enzyme that removes triglycerides from intermediate-density lipoproteins (IDL), leading to the development of smaller, denser low-density lipoproteins, including LDL. In MASLD and insulin resistance, hepatic lipase levels are upregulated, resulting in increased levels of small, dense LDL particles (58). Insulin resistance can further increase circulating LDL levels by reducing LDL receptor abundance. Insulin upregulates proprotein convertase subtilisin/kexin type 9 (PCSK9), a circulating protein that binds to and promotes degradation of the LDL receptor (59). Increased PCSK9 expression decreases LDL receptor availability on hepatocytes, thereby elevating circulating LDL concentrations.

INSULIN RESISTANCE DECREASES CIRCULATING HDL LEVELS

In addition to the changes in LDL metabolism, upregulation of hepatic lipase contributes to reduced HDL-cholesterol concentrations by hydrolyzing triglyceride-enriched HDL particles. This in turn leads to dissociation of apoA-1 from HDL particles and accelerated renal clearance (60, 61). Insulin resistance also decreases circulating HDL levels by interfering with HDL particle assembly. HDL is formed within plasma at the hepatocyte surface and requires the interaction of ApoA-1 and ATP-binding cassette transporter A1 (ABCA1) (62). Nascent HDL particles are formed when ApoA-1, secreted by the liver or released from other lipoproteins, is lipidated with phospholipids and free cholesterol by ABCA1. Insulin resistance hampers HDL formation by promoting the phosphorylation and degradation of ABCA1 and by reducing ABCA1 activity (63). In addition to hampering HDL production and promoting catabolism, insulin resistance may interfere with reverse cholesterol transport. Insulin resistance can result in the formation of triglyceride-rich HDL particles owing to the action of cholesterol ester transfer protein (CETP) (64). These triglyceride-rich HDL are cleared more efficiently by the liver, further contributing to reduced circulating HDL levels.

Management

Diet and exercise are the foundations of the management of both MASLD and the associated dyslipidemia. Small studies have indicated that both a low carbohydrate diet as well as the Mediterranean diet may improve both serum lipids and MASLD (65-67). Further, adherence to a Mediterranean diet reduces the development of CVD (68). As CVD is a cause of considerable morbidity and mortality in MASLD patients, adherence to a Mediterranean diet may have benefits beyond liver disease per se.

Routine aerobic exercise, defined as 30 minutes of moderate exercise most days of the week, can result in significant improvements in lipid levels and may improve hepatic lipid content (69, 70). Individuals with MASLD should be advised to engage in aerobic exercise on a regular basis.

Given the weight loss, improved glycemic control and reduced risk of major cardiovascular events associated with glucagon-like peptide-1 receptor agonists (GLP-1RA), such as semaglutide (71), their potential efficacy has been evaluated in MASLD and MASH. GLP-1RA treatment has been shown to reduce liver fibrosis in patients with MASH with moderate or advanced fibrosis (72), as well as to lower circulating triglycerides and total cholesterol levels. Based on these effects, semaglutide received accelerated FDA approval in 2025 for the treatment of adults with non-cirrhotic MASH, with continued approval contingent upon confirmatory clinical outcomes data. However, no improvement in LDL-C levels has been observed, suggesting that additional lipid-lowering strategies may be required to adequately mitigate cardiovascular risk (73).

The first pharmacological therapy approved for MASH, is the liver-directed selective thyroid hormone receptor-β agonist resmetirom, which targets key pathways involved in lipid metabolism and inflammation (74). A meta-analysis revealed reductions in LDL-C, triglycerides, Lp(a), apoB and apoCIII (75). MASH resolution was achieved in 25.9% to 29.9% of patients, depending on the dose, compared with only 9.7% of patients who received placebo (76).

OTHER LIPID-LOWERING MEDICATIONS

HMG-CoA Reductase Inhibitors

When diet and exercise are insufficient in individuals with MASLD, HMG-CoA reductase inhibitors or “statins” are recommended. Statins play an important role in both the primary and secondary prevention of CVD and should be considered in patients with MASLD. In a post-hoc analysis of the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study, statin therapy significantly reduced cardiovascular events in individuals with MASLD compared to placebo (77). Beyond cardiovascular benefit, statins have also been shown to exert protective effects on liver histology in patients with MASLD/MASH, including dose-dependent reduction in steatosis, steatohepatitis and fibrosis stages F2-F4. However, protection against steatohepatitis in individuals carrying the I148M PNPLA3 risk variant did not reach statistical significance (78).

Despite these benefits, concerns regarding statin-associated hepatotoxicity persist among many physicians. Importantly, the incidence of statin-induced hepatotoxicity in the general population is extremely low and is not increased in individuals with MASLD or MASH (79-81). This ongoing apprehension among physicians may partly explain the under-prescribing of statins in patients with MASLD (78, 82).

Omega-3 Fatty Acids

Omega-3 fatty acids may be used in patients with MASLD for the treatment of isolated hypertriglyceridemia or when statins alone are insufficient to control triglyceride levels. Omega-3 fatty acids act to reduce hepatic VLDL secretion and lower serum triglyceride levels. Doses of up to 4 grams daily can decrease triglycerides by 25-35% (83). Omega-3 fatty acids may reduce hepatic steatosis and aminotransferases (84-86).

Cholesterol Absorption Inhibitors

Cholesterol absorption inhibitors, among which ezetimibe has been the most extensively studied, have shown promise in MASLD. A randomized controlled trial (RCT) involving 32 patients with MASLD demonstrated that ezetimibe use led to significant improvements in fibrosis stage and ballooning score (87). However, ezetimibe did not significantly reduce liver fat content, as assessed by magnetic resonance imaging-proton density fat fraction and liver biopsy (88). Consequently, the influence of ezetimibe across the various stages of MASLD pathogenesis remains to be fully characterized.

LIPID TREATMENT GOALS

Treatment goals for cholesterol levels are guided by the Clinical Practice Guidelines from the American Heart Association and American College of Cardiology (89) and the Guidelines for the management of dyslipidaemias from the European Society of Cardiology and European Atherosclerosis Society (90). These guidelines recommend high-intensity statin therapy for all adults with any form of CVD or an LDL-C ≥ 190 mg/dL, with a target of at least 50% reduction in LDL-C. Patients aged 45-70 years with diabetes and an LDL-C < 189 mg/dL, as well as individuals with a calculated 10-year global CVD-risk > 7.5%, should receive moderate-intensity statins therapy, aiming for a 30-50% reduction in LDL-C. Notably, a specific LDL-C target is no longer formally recommended.

Return to Case

For the patient with MASLD, lipid-lowering medication to manage dyslipidemia and reduce the risk of heart attack or stroke would be both safe and beneficial.

Table 2.

Management of Dyslipidemia in the setting of Metabolic Dysfunction-Associated Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH)

MASLD is associated with insulin resistance, which contributes to atherogenic dyslipidemia characterized by increased small dense LDL and triglycerides and decreased HDL.

The dyslipidemia of MASLD may contribute to the increased risk of CVD

Dyslipidemia in patients with MASLD and MASH should be treated to reduce their CVD risk.

Combined treatment with resmetirom and semaglutide or with other lipid-lowering drugs may achieve better results than monotherapy.

Individuals with MASLD can be treated with statins without increased risk of hepatotoxicity.

ALCOHOLIC LIVER DISEASE

Case Presentation

An obese 48-year-old man with a past medical history significant for coronary heart disease, hypertension, and diabetes mellitus presents for management of newly diagnosed hepatic steatosis. He has a family history of coronary artery disease. He reports consuming 3 glasses of wine per night during the week (approximately 42 g alcohol daily) and an additional two glasses per evening on weekends. His fasting plasma triglyceride concentration is 350 mg/dL, his LDL cholesterol is 130 mg/dL, and HDL cholesterol is 55 mg/dL. The alanine aminotransferase level (ALT) is modestly elevated at 55 IU/L. He would like to know whether he has MASLD and whether you recommend continuing his current alcohol intake to protect against CVD, especially since he was told that his good cholesterol was elevated.

Introduction

Metabolic dysfunction and alcohol-associated liver disease (MetALD) reflects a recently adopted classification for patients with MASLD who consume 140-350 g per week for women or 210-420 g per week for men, and have at least one metabolic risk factor, such as obesity, hypertension or type 2 diabetes (2, 91). In contrast, alcohol-associated liver disease (ALD) is diagnosed in individuals whose alcohol consumption exceeds these thresholds. These updated diagnostic criteria help identify distinct patient populations, thereby facilitating the design of more targeted and effective therapeutic interventions.

Alcohol-associated liver disease (ALD) accounts for nearly half of cirrhosis-related mortality in the United States (92). A hallmark feature of ALD is hepatic steatosis, which develops in more than 90% of heavy drinkers. However, less than one third of these individuals progress to advanced liver disease, including alcoholic hepatitis, cirrhosis, and HCC (92). Risk factors for disease progression include female sex, obesity, drinking patterns, dietary factors, non–sex-linked genetic factors, and cigarette smoking (93, 94).

Alcohol also synergizes with other etiologies of chronic liver diseases, including MASLD and viral hepatitis, to accelerate disease progression (92). Hypertriglyceridemia is the predominant dyslipidemia associated with alcohol consumption (95), and a J-shaped association exists between alcohol intake and CVD risk (96), which may reflect a parallel effect of plasma triglycerides (95). Although the contribution of alcohol to metabolic syndrome remains unclear, alcohol intake appears to interact with obesity to further increase plasma triglyceride concentrations (95).

Changes in Lipoprotein Metabolism and Clinical Manifestations

DEVELOPMENT OF STEATOSIS

As with MASLD, the development of steatosis in response to alcohol is multifactorial. Alcohol impairs the β-oxidation of fatty acids by mitochondria, promotes de novo lipogenesis in the liver, and increases fatty acid uptake. VLDL secretion is also increased in response to alcohol.

Excess FFA Delivery to the Liver

Fatty acids from extrahepatic sources appear to contribute substantially to hepatic steatosis. In addition to increasing mobilization of fatty acids from adipose tissue (97), alcohol intake augments hepatic lipid supply from the small intestine in the form of chylomicron remnants (98).

Increased Denovo Lipid Synthesis

Increased DNL synthesis contributes to alcohol-related steatosis through both direct and indirect mechanisms (92). The alcohol metabolite acetaldehyde increases transcription of SREBP1c, which upregulates transcription of lipogenic genes. In parallel, alcohol-induced endoplasmic reticulum stress and inflammation enhance proteolytic processing and activation of SREBP1c protein within hepatocytes. Alcohol also inhibits key suppressors of lipogenesis, most notably the protein deacetylase Sirtuin 1 (SIRT1), which plays a central role (99). Alcohol-mediated suppression of SIRT1 leads to hyperacetylation of multiple targets, including factors that promote lipogenesis. In addition, inhibition of adenosine monophosphate-activated protein kinase (AMPK) further contributes to increased lipogenesis. AMPK normally suppresses lipogenesis by phosphorylating SREBP1c, thereby reducing its transcriptional activity, and by phosphorylating and inhibiting acetyl-CoA carboxylate (ACC), the rate-limiting enzyme in fatty acid synthesis.

Impaired Oxidation and Degradation of Fatty Acids

Alcohol decreases mitochondrial fatty acid oxidation principally by decreasing activity of the transcription factor peroxisome proliferator activated receptor alpha (PPARα). This occurs in response to increased NADH/NAD+ ratios and decreased AMPK activity, among other factors (92). PPARα promotes the transcription of genes that mediate fatty acid oxidation. Alcohol intake may also inhibit autophagy (92), which plays an important role removing lipids from the liver (100).

Insufficient Export of Hepatic Triglycerides

Alcohol increases VLDL secretion (95, 101), apparently by increasing the transcription of MTP (97). The increase in export of hepatic triglycerides is insufficient to offset the accumulation due to increases in fatty acid uptake and synthesis in the setting of decreased oxidation.

HYPERTRIGLYCERIDEMIA

Increased VLDL secretion contributes to hypertriglyceridemia that is observed in the setting of alcohol consumption. This is exacerbated by decreased expression of LPL (102), which promotes clearance of VLDL triglycerides into muscle and fat tissue. There is also an interaction between alcohol consumption and genetic polymorphisms in apoCIII, which circulates in the plasma and functions to inhibit lipoprotein lipase activity (103).

HDL LEVELS

Alcohol increases HDL lipids and apolipoproteins in a manner that depends on the amount of consumption. Moderate consumption tends to increase plasma concentrations of smaller HDL particles, whereas heavier consumption favors the accumulation of larger HDL particles (81). Alcohol influences HDL metabolism at multiple steps, ultimately leading to increased reverse cholesterol transport, the process by which cellular cholesterol is transported to the liver for elimination into bile (104, 105). Heavier alcohol consumption impairs CETP activity, as a result, the typical inverse relationship between CETP activity and HDL levels observed in MASLD is not necessarily maintained in the setting of alcohol use, and HDL concentrations may be increased as well (95, 106). Moderate alcohol consumption also appears to enhance the anti-inflammatory and anti-oxidant properties of HDL particles (104).

LDL LEVELS

The effects of alcohol on plasma LDL cholesterol concentrations is less consistent than observed for HDL, with different patterns observed in different populations, which may be attributable to genetic polymorphisms with these populations (104).

Table 3.

Alterations in Plasma Lipids and Lipoprotein in the setting of Metabolic dysfunction- and alcohol-associated liver disease (MetALD)

Plasma triglycerides	↑
VLDL production/particles	↑
LDL cholesterol	↔ or ↑
HDL cholesterol	↑
Lp(a)	Typically normal

Management

In the setting of MetALD, cessation of drinking, along with therapeutic lifestyle modifications -including behavioral and psychological treatments- are the mainstays of therapy. Pharmacological management of MetALD should address both metabolic dysfunction and alcohol-related pathways (91). For the metabolic component, agents approved for MASLD, such as the thyroid hormone receptor-β agonist resmetirom, may be considered (76). Treatment responses to resmetirom in patients meeting criteria for MetALD were comparable to those observed in the overall MASLD population (107). In addition, GLP-1RA have demonstrated efficacy in reducing hepatic steatosis and improving liver biochemistry (72). Emerging evidence further suggests that GLP-1RA may also reduce alcohol consumption (108).

Return to Case

The diagnosis of MASLD is based on the absence of significant alcohol consumption. For a man, the upper limit of alcohol intake is 2 drinks per day (28 g/day). This means that this patient is categorized as MetALD. Conceptually, MetALD reflects the synergistic interaction between alcohol exposure and metabolic dysregulation, which together exacerbate steatohepatitis, fibrosis, hepatocellular carcinoma, and extrahepatic complications. He is at high risk for CVD, so should be managed accordingly, including lipid-lowering therapy with statins. His alcohol consumption should be reduced to less than 2 drinks per day, which may help reduce his fasting triglyceride concentrations. He should not be falsely reassured by his elevated HDL cholesterol concentration.

Table 4.

Key Points - Metabolic dysfunction- and Alcohol-Associated Liver Disease (MetALD)

The consumption of alcohol is a common cause of excess fat accumulation in the liver.

There are multiple mechanisms by which alcohol promotes hepatic steatosis.

Alcohol can increase plasma HDL cholesterol concentrations and fasting triglyceride concentrations.

Although modest alcohol consumption is associated with reduced CVD risk, this cannot be recommended due to other potential adverse effects, including alcoholic liver disease.

VIRAL HEPATITIS - C

Case Presentation

A 65-year-old woman with a past medical history of CVD and untreated genotype 1 chronic hepatitis C presents for management of CVD. Her lipid levels are notable for an LDL of 99. She has read that since her LDL is below the recommended level for patients with CVD she would not benefit from lipid-lowering therapy. What would you advise her?

Introduction

Hepatitis C virus (HCV) is a positive-strand RNA virus of the family Flaviviridae that can lead to chronic infection as well as the development of cirrhosis, HCC, and the need for liver transplantation. Chronic HCV (CHC) infection affects between 130 and 170 million individuals worldwide (109) .

Changes in Lipoprotein Metabolism

HCV replication is intricately linked with host cell lipids and impacts host lipid metabolism. Circulating HCV virions complex with host lipoproteins and form lipoviroparticles (110). This lipid-rich composition is a prerequisite for maintenance of viral particle morphology and HCV infectivity (111-114). For example, lipids on the virion surface shield viral envelope epitopes, protecting them from antibody engagement (115). Lipoviroparticles can enter hepatocytes via multiple receptors including the hepatocyte LDL receptor, which may also facilitate the replication step of the HCV cycle (116). Additional host factors involved in viral entry include Niemann-Pick C1-like 1 (NPC1L1), a receptor for cholesterol resorption, and scavenger receptor class B member 1 (SRB1), which acts to promote cholesterol uptake from lipoproteins, and interacts with HCV envelope glycoprotein E2 to promote HCV entry (117-119). LDL receptor and SRB1 appear to have a redundant role in HCV entry (120). Several apolipoproteins influence HCV uptake: apoC1 interacts with HCV glycoproteins to promote infection, and apoE mediates initial attachment between virus and hepatocyte. Hepatocyte VLDL receptor mediates an additional HCV entry mechanism, involving E2 and apoE, with increased VLDL receptor expression conferring greater susceptibility to infection (121). Formation of the HCV core protein involves interaction with host cytosolic lipid droplets and with diacylglycerol O-acetyltransferase 1 (DGAT1), a host enzyme involved in triglyceride synthesis. HCV replication also depends on host cholesterol biosynthesis pathways within hepatocytes. The host protein F-box and leucine-rich repeat protein 2 (FBL2) undergoes geranylgeranylation, a post-translation modification derived from an intermediate of the cholesterol synthesis pathway that is essential for replication complex stability (122). Disruption of this pathway extinguishes HCV replication. Finally, HCV secretion from hepatocytes involves complexing with apoE-containing host lipoproteins in the form of VLDL or HDL (123).

Clinical Manifestations

Like MASLD, HCV infection is associated with the development of hepatic steatosis. However, unlike MASLD, HCV is also associated with hypolipidemia. Chronic HCV infection leads to significantly lower host LDL and total cholesterol levels than uninfected controls (124). Treatment is associated with increases in both LDL and cholesterol levels in patients with HCV who achieve a cure, defined as a sustained virologic response (SVR). Changes in host serum lipids are also seen in patients with acute HCV. Acute HCV infection is associated with a decrease in total cholesterol, LDL and non-HDL-C from pre-infection levels. In addition, total cholesterol, LDL, triglycerides and non-HDL-C progressively decline over a 10-year period following HCV seroconversion, after adjusting for BMI and FIB-4 score (125). In patients who achieved viral clearance, either spontaneous or treatment-induced, total cholesterol, LDL and non-HDL-C increased significantly from infection levels. In patients with both acute and chronic infection, post-viral clearance lipid levels exceed pre-infection levels (126).

While HCV infection is associated with decreased LDL and non-HDL-C, which are important CVD risk factors, HCV infection is associated with an increased overall risk of CVD (127, 128). When non-HCV infected individuals with similar lipid levels are compared to those with chronic HCV, HCV infection independently confers an increased risk of acute myocardial infarction (AMI), with a more pronounced increase seen in younger individuals (129). Further, lipid-lowering therapy among individuals with chronic HCV was associated with a greater reduction in AMI risk than uninfected persons with similar lipid levels. Therefore, lipid levels may not accurately reflect CVD risk in patients with chronic HCV.

Table 5.

Alterations in Plasma Lipids and Lipoprotein in the setting of Hepatitis C

	Infection	Post-treatment
Plasma triglycerides	Normal or mildly ↑	variable
Total cholesterol	↓	↑ (rapid onset)
LDL cholesterol	↓	↑
HDL cholesterol	↓	↑
ApoB	↓	↑
Lp(a)	↓	↑

Management

Lipid treatment goals for individuals with chronic HCV are not well established. It is recommended that patients with chronic HCV adhere to the Cholesterol Clinical Practice Guidelines from the American Heart Association and American College of Cardiology (89). Retrospectively-collected data links statin use to improved liver-related outcomes, with higher likelihood of achieving SVR, and lower rates of fibrosis progression, cirrhosis development, HCC incidence, and mortality amongst patients with chronic HCV (130-133). The use of atorvastatin and fluvastatin have the most significant anti-fibrotic benefit, compared with simvastatin, pravastatin, lovastatin or no statin use (134). It is important to note that for individuals who have achieved an SVR after HCV treatment, lipid levels often increase to or above pre-infection levels. Induction of SVR using direct-acting antiviral (DAA) therapy led to pro-atherogenic lipid changes (increased total cholesterol, LDL, LDL/HDL ratio, and non-HDL-C), irrespective of DAA regimen or fibrotic stage, with a parallel reduction in insulin resistance. The balance of these effects with respect to CVD risk remains to be determined (135). Greater increases in serum LDL-cholesterol (LDL-C) levels in patients undergoing therapy were observed with ledipasvir/sofosbuvir treatment compared to daclatasvir/asunaprevir. Decline in HCV core protein was also independently associated with increases in LDL-C as lipid metabolism normalized (136). Thus, practitioners should be mindful to monitor post-treatment lipid levels and treat appropriately. Recent studies indicate that even years after HCV eradication, a substantial proportion of individuals develop MASLD accompanied by persistent dyslipidemia, suggesting ongoing metabolic risk despite SVR (137).

Return to Case

For the patient with CHC and CVD it would be important to administer lipid-lowering therapy to reduce the risk of a second CVD event. Based on the guidelines, she would benefit from high-intensity statin therapy, with a goal of decreasing LDL cholesterol by >50%.

Table 6.

Key Points - Hepatitis C Infection Modulates Lipid and Lipoprotein Metabolism

The hepatitis C virus interacts with host lipids for hepatocyte entry, viral replication and secretion.

HCV infection decreases host serum LDL and total cholesterol levels.

Despite lower cholesterol levels, HCV infection is still associated with an increased risk of AMI and treatment with statins reduces this risk.

Eradication of HCV results in increased serum lipid levels to at least pre-infection levels. As a result, some patients may newly meet the criteria for lipid-lowering therapy following cure.

VIRAL HEPATITIS - B

Introduction

Approximately 250 million individuals worldwide are chronically infected with the hepatitis B virus (HBV) (138, 139). Like HCV, chronic HBV infection can lead to cirrhosis and hepatocellular carcinoma.

Lipoprotein Metabolism in Hepatitis B

HBV interacts with host lipid metabolism at several critical stages, including during viral cell entry and formation of essential viral proteins such as the HBV surface antigen. HBV uses the sodium-taurocholate cotransporting polypeptide (NTCP), a plasma membrane protein that facilitates hepatocellular uptake of bile acids from the plasma (140). HBV binding to NTCP impairs the bile acid transport function of NTCP resulting in increased conversion of cholesterol to bile acids within hepatocytes.

The formation of the HBV surface antigen within hepatocytes relies in part on host cell cholesterol (141). The surface antigen particle is synthesized in the endoplasmic reticulum (ER) and is associated with the host ER lipid bilayer. Association with the lipid bilayer helps make the particle resistant to degradation by cellular proteases. The surface antigen is then transported to the ER lumen and exported from the hepatocyte as a lipoprotein particle. Approximately 25% of the surface antigen complex is composed of host lipids including phosphatidylcholine, triglycerides, cholesterol and cholesterol esters (141).

HBV infection may also alter lipogenic gene expression. Two studies have demonstrated increased lipogenic gene expression in HBV-infected transgenic mice. HBV-infected transgenic mice exhibit increased gene expression of SREBP2, 3-hydroxy-3-methylglutaryl-coenzyme A reductase, LDL receptor, fatty acid synthase, and ATP citrate lyase, all of which play a role in either cholesterol metabolism or fatty acid synthesis (142, 143). In HBV infected humanized mice, gene expression of the HDL-associated human apolipoprotein A1, which plays a role in reverse cholesterol transport and PPAR-γ which regulates adipocyte differentiation and fatty acid storage, were significantly enhanced (142). HBV-infected transgenic mice also demonstrate elevated levels of cholesterol 7α-hydroxylase (hCYP7A1), which promotes bile acid formation from cholesterol. In liver biopsy samples from patients with chronic HBV infection, hCYP7A1 was significantly induced when compared to uninfected controls. Taken together, these findings suggest that HBV replication may impact cholesterol metabolism.

Clinical Manifestations

Data on the impact of HBV infection on circulating lipid levels in humans remain limited. HBV infection may be associated with lower triglyceride levels compared with uninfected individuals (144); however, its influence on HDL remains ambiguous. In a case-control study comparing 322 individuals with chronic HBV infection to 870 age-matched uninfected controls, HBV-infected individuals exhibited significantly lower triglyceride and HDL levels than controls (144). In a second retrospective cohort of 122 individuals with chronic HBV, HBV DNA levels were inversely correlated to serum triglyceride levels, whereas no association was observed with HDL levels (144). In a separate cohort of non-diabetic patients, hepatitis B surface antigen (HBsAg) seropositivity was inversely associated with hypertriglyceridemia and low HDL cholesterol. Hence, chronic HBV infection may favorably impact lipid profiles, which could partly account for the inverse relationship between HBsAg-seropositivity, and metabolic syndrome observed in this cohort (145). Similarly, HBsAg-positivity was associated with lower risk of developing dyslipidemia during a mean follow up of 4.5 years among patients without dyslipidemia at baseline (146).

Circulating lipid levels may be predictive of clinical outcomes in HBV-infected patients. The average plasma apolipoprotein A-V level was decreased amongst 209 non-survivors of HBV-acute on chronic liver failure versus 121 survivors (147).

Like HCV, chronic HBV infection is frequently associated with hepatic steatosis. Between 25% and 51% of patients with HBV were found to harbor steatosis by imaging or biopsy (148). However, while concurrent steatosis is common in HBV infections, steatohepatitis is not frequently described. Further, the pathogenesis of steatosis in HBV is not well understood and may be related to co-existing metabolic factors such as body mass index (BMI) and insulin resistance rather than the viral infection per se (149).

Management

Because data on the impact of HBV infection on circulating lipids are limited, there are no formal guidelines for dyslipidemia management in this population. Clinicians should be mindful of a possible decrease in HDL in this population and follow standard guidelines from the American Heart Association and American College of Cardiology on lipid management. Recent studies have shown reduced risk of cirrhosis development (150), decompensation (150-153), mortality (151, 152) and portal hypertension (151) amongst statin users compared to non-users with chronic HBV- and HCV-related hepatitis. Furthermore, statin use was associated with a 32% reduction in HCC risk. Concomitant use of statin and nucleos(t)ide analogue led to an additive chemopreventive effect (154). RCTs would be needed to comprehensively evaluate statins as a means of protection against disease progression in patients with viral hepatitis.

Table 7.

Key Points- Hepatitis B

HBV infection may interact with host lipid metabolism and enhance lipogenic gene expression

The clinical manifestations of HBV on host lipids are not well understood, but HBV infection may decrease serum triglyceride and HDL levels.

Management of patients with HBV and dyslipidemia should be guided by standard recommendations for the treatment of dyslipidemia.

CHOLESTATIC DISEASES

Case Presentation

A 58-year-old woman is referred with primary biliary cholangitis (formerly primary biliary cirrhosis; PBC) for the management of an elevated plasma total cholesterol of 450 mg/dL. She only reports symptoms of mild and intermittent pruritus. She is currently taking ursodeoxycholic acid. Her physical examination is notable for xanthelasma under the eyes.

Introduction

Bile is the primary route for cholesterol elimination from the body. Plasma cholesterol is taken up by the liver in the form of apolipoprotein B-containing lipoproteins (i.e. remnant lipoproteins and LDL) through receptor-mediated endocytosis, as well as via selective uptake of HDL cholesterol (155). Cholesterol is subsequently eliminated either by conversion to bile salts or by direct biliary secretion. Biliary obstruction, particularly in the setting of cholestatic liver diseases, can interfere with cholesterol elimination leading to hypercholesterolemia. This occurs most commonly in the setting of PBC, which is an autoimmune-mediated destruction of intrahepatic bile ducts. Similar disturbances can also occur in primary sclerosing cholangitis (PSC), in which there is inflammatory stricturing of larger bile ducts.

Lipoprotein Metabolism in Cholestasis

Hypercholesterolemia associated with cholestasis is largely attributable to the formation of lipoprotein-X, an atypical lipoprotein particle. Lipoprotein-X comprises principally unesterified cholesterol and phospholipids (156), resembling the cholesterol-phospholipid vesicles that are secreted by the liver into bile (157). The lipids of the particle comprise a sphere, with an aqueous core. The principal proteins associated with lipoprotein-X are apoC and albumin contained within the core (158, 159). It appears to be formed due to the secretion of biliary-type particles into plasma in the setting of obstruction to bile flow (160), although defects in plasma cholesterol esterification may also contribute (156). Lipoprotein-X has similar characteristics as LDL including density, so that its presence in plasma requires electrophoretic separation (161). Because lipoprotein electrophoresis is not routinely available in most clinical laboratories, clinicians may rely instead on the discordance between apoB and non–HDL-C concentrations to raise suspicion for the presence of lipoprotein-X. Because lipoprotein-X is devoid of apoB, circulating apoB levels are disproportionately low relative to the markedly elevated non–HDL-C concentration. Table 8 illustrates the expected relationship between non–HDL-C and apoB based on population data from the UK Biobank (162).

Table 8.

Non-HDL-C Level and Variation in Apo B Level

Non-HDL-C (mg/dL)	Apo B (mg/dL) (Range of 95% of values)
100	52-78
130	73-95
160	88-112
190	105-131
220	119-151

Plasma total cholesterol concentrations are increased in PBC in proportion to disease severity, with elevations that can be striking and exceed 1,000 mg/dL, and can be a rare cause of pseudohyponatremia (158). Where these elevations are primarily attributable to lipoprotein-X, apolipoprotein B concentrations may also be elevated due to abnormal lipoprotein metabolism associated with liver disease (156, 158). Serum metabolomics analysis of patients with PBC have revealed elevated levels of VLDL and LDL compared to controls (163). HDL cholesterol concentrations may be elevated in the early stages of PBC and tend to decline as the disease progresses (164), apparently because of increased hepatic lipase activity that promotes HDL catabolism (156). Patients with more advanced PBC exhibit increased plasma triglycerides (156), presumably owing to decreased hepatic lipase activity (164).

Plasma lipids in PSC have been less well characterized than in PBC. In a small series (165), hypercholesterolemia was more modest than generally observed in PBC, but did increase in concert with disease severity. HDL cholesterol levels tended to be high, but triglyceride elevations were uncommon.

Clinical Manifestations

An important clinical question has been whether the lipid abnormalities associated with cholestatic diseases confer increased CVD risk. This has been studied more extensively in PSC in the form of prospective trials (164, 166). Although each had limitations, collectively there was no suggestion of increased atherosclerotic events, which is in keeping with the relative absence of elevations in atherogenic particles There is also evidence in vitro to suggest that lipoprotein-X may be atheroprotective by reducing oxidation of LDL (161). In patients with PBC, the presence of xanthelasma does not appear to connote an increased CVD burden (164).

As with PBC, the cholesterol elevations associated with PSC do not appear to confer CVD risk. None was observed in the small series cited above, but it was acknowledged that patients were young enough that excess CVD events would not have been expected (165). Lipid levels ultimately fell in patients who had progressed to cirrhosis and hepatic failure.

Management

Due to the overall lack of clinical evidence, the management of hypercholesterolemia associated with cholestasis lacks formal recommendations. In PBC, ursodeoxycholic acid (UDCA) slows the progression of the disease and prolongs survival (167). Chronic UDCA administration also reduces plasma LDL concentrations. In PBC patients, statin therapy is generally safe and is effective at lowering LDL cholesterol in PBC patients (79, 168-170). At present, UDCA is generally not recommended in the management of PSC (171), and data are lacking regarding lipid-lowering therapies in these patients. Of note, some patients with obstructive jaundice are treated with bile acid binders to reduce pruritus and not primarily to reduce plasma cholesterol concentrations. Plasmapheresis may be used to reduce plasma cholesterol and suppress disease progression (172).

Return to Case

For the patient with PBC, the presence of lipoprotein-X may be confirmed by lipoprotein electrophoresis. The possible contribution of atherogenic particles may be estimated by the measurement of the plasma apoB concentration. The institution of statin therapy should be based on standard estimates of CVD risk.

Table 9.

Key Points- Cholestatic Disease

Plasma total cholesterol concentrations are commonly elevated in the setting of cholestasis.
ApoB levels tend to be lower than predicted by non-HDL cholesterol levels.

Lipoprotein-X is a lipoprotein that circulates in patients with cholestasis and is primarily responsible for the elevations in plasma total cholesterol concentrations.

Elevations in plasma cholesterol concentrations due to cholestasis do not appear to confer excess CVD risk.

Patients with cholestatic disorders may be candidates for lipid-lowering therapy if they are otherwise at risk for CVD.

CIRRHOSIS

Introduction

Cirrhosis represents the common advanced histopathologic endpoint of chronic liver diseases, in which the formation of fibrotic nodules often obscures the underlying disease etiology. Clinical manifestations span a broad spectrum, ranging from well-compensated liver function with no apparent clinical manifestations to advanced decompensated liver disease characterized by portal hypertension and complications such as hepatic encephalopathy, esophageal varices, and ascites. Moreover, the development of cirrhosis confers increased risk of HCC.

Changes in Lipoprotein Metabolism and Clinical Manifestations

The changes in lipoprotein metabolism associated with cirrhosis generally reflect the degree of impairment of hepatic function. In one study (173), plasma concentrations of total cholesterol, HDL cholesterol, LDL cholesterol, and VLDL cholesterol varied with increases in prothrombin time and decreases in serum albumin, which reflect hepatic synthetic function. These findings are in general agreement with other studies (174). Lipoprotein compositions are also altered in the setting of cirrhosis, with LDL particles enriched with triglycerides and deficient in cholesteryl esters, as well as HDL particles enriched with triglycerides, free cholesterol and phospholipids (174). These changes are secondary to characteristic abnormalities in plasma enzymes that remodel lipoproteins, including lecithin-cholesterol acyl transferase (LCAT), hepatic lipase, and phospholipid transfer protein (PLTP) (174). HDL cholesterol and enzymes involved in HDL maturation and metabolism are decreased in patients with cirrhosis. There is a shift in the composition of HDL in those with cirrhosis towards the larger HDL2 subclass and a reduction in small HDL3 particles. The latter are associated with diminished cholesterol efflux capacity, and their concentrations are predictive of 1-year mortality (175).

Table 10.

Alterations in Plasma Lipids and Lipoprotein in the setting of Cirrhosis

Plasma triglycerides	↓
VLDL production/particles	↓
LDL cholesterol	↓ (↓↓ in decompensated cirrhosis)
HDL cholesterol	↓↓
Non-HDL cholesterol	↓
Lp(a)	↓ ↓

HCC can occur in the setting of cirrhosis and may be associated with alterations in plasma lipid concentrations (176-178). In the case of hypercholesterolemia, the increase may be driven by elevated rates of cholesterol synthesis and cellular levels of 3-hydroxy-3-methylglutarylcoenzyme A. It is unclear whether hypercholesterolemia in this context confers increased CVD risk (179, 180). CVD risk is dependent upon the etiology of cirrhosis, at least in part due to the association of type 2 diabetes. Cirrhosis due to MASH, HCV, and alcoholic liver disease increases the risk of type 2 diabetes, which is not observed in cholestatic liver diseases and presumably contributes to CVD risk (174, 181).

Management

Statin therapy can be safely administered in patients with compensated cirrhosis and elevated CVD risk (79). In individuals with non-cholestatic cirrhosis, low HDL cholesterol serves as a surrogate marker of liver function and is an indicator of poor prognosis, including an increased risk of cirrhosis-related mortality (182). Use of GLP-1RA in patients with MASLD and diabetes, has been associated with a reduced risk of progression to cirrhosis and lower mortality. However, this protective association has not been observed in individuals with established cirrhosis, suggesting that potential benefits may be greater when therapy is initiated earlier in the disease course (183).

ACKNOWLEDGEMENT

The contributions of Kathleen Corey, MD MPH, MMSc to previous versions of this chapter are gratefully acknowledged.

REFERENCES

1.: Eslam, M., et al., A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol, 2020. 73(1): p. 202-209. [PubMed: 32278004]
2.: Rinella, M.E., et al., A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology, 2023. 78(6): p. 1966-1986. [PMC free article: PMC10653297] [PubMed: 37363821]
3.: Williams, C.D., et al., Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology, 2011. 140(1): p. 124-31. [PubMed: 20858492]
4.: Browning, J.D., et al., Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology, 2004. 40(6): p. 1387-95. [PubMed: 15565570]
5.: Younossi, Z.M., et al., The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology, 2023. 77(4): p. 1335-1347. [PMC free article: PMC10026948] [PubMed: 36626630]
6.: Corey, K.E. and N. Chalasani, Management of dyslipidemia as a cardiovascular risk factor in individuals with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol, 2014. 12(7): p. 1077-84; quiz e59-60. [PMC free article: PMC3933450] [PubMed: 23962548]
7.: Targher, G., C.D. Byrne, and H. Tilg, NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut, 2020. 69(9): p. 1691-1705. [PubMed: 32321858]
8.: Alves-Bezerra, M. and D.E. Cohen, Triglyceride Metabolism in the Liver. Compr Physiol, 2017. 8(1): p. 1-8. [PMC free article: PMC6376873] [PubMed: 29357123]
9.: Kawano, Y. and D.E. Cohen, Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol, 2013. 48(4): p. 434-41. [PMC free article: PMC3633701] [PubMed: 23397118]
10.: Arguello, G., et al., Recent insights on the role of cholesterol in non-alcoholic fatty liver disease. Biochim Biophys Acta, 2015. 1852(9): p. 1765-78. [PubMed: 26027904]
11.: Miquilena-Colina, M.E., et al., Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C. Gut, 2011. 60(10): p. 1394-402. [PubMed: 21270117]
12.: He, J., et al., The emerging roles of fatty acid translocase/CD36 and the aryl hydrocarbon receptor in fatty liver disease. Exp Biol Med (Maywood), 2011. 236(10): p. 1116-21. [PubMed: 21885479]
13.: Choi, S.H. and H.N. Ginsberg, Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance. Trends Endocrinol Metab, 2011. 22(9): p. 353-63. [PMC free article: PMC3163828] [PubMed: 21616678]
14.: Sanders, F.W. and J.L. Griffin, De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose. Biol Rev Camb Philos Soc, 2016. 91(2): p. 452-68. [PMC free article: PMC4832395] [PubMed: 25740151]
15.: Uyeda, K. and J.J. Repa, Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. Cell Metab, 2006. 4(2): p. 107-10. [PubMed: 16890538]
16.: Wetterau, J.R., et al., Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science, 1992. 258(5084): p. 999-1001. [PubMed: 1439810]
17.: Berriot-Varoqueaux, N., et al., The role of the microsomal triglygeride transfer protein in abetalipoproteinemia. Annu Rev Nutr, 2000. 20: p. 663-97. [PubMed: 10940349]
18.: Goh, V.J. and D.L. Silver, The lipid droplet as a potential therapeutic target in NAFLD. Semin Liver Dis, 2013. 33(4): p. 312-20. [PubMed: 24222089]
19.: Tanoli, T., et al., Fatty liver in familial hypobetalipoproteinemia: roles of the APOB defects, intra-abdominal adipose tissue, and insulin sensitivity. J Lipid Res, 2004. 45(5): p. 941-7. [PubMed: 14967820]
20.: McGowan, M.P., et al., Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS One, 2012. 7(11): p. e49006. [PMC free article: PMC3496741] [PubMed: 23152839]
21.: Fisher, E.A. and H.N. Ginsberg, Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins. J Biol Chem, 2002. 277(20): p. 17377-80. [PubMed: 12006608]
22.: Chamberlain, J.M., et al., Insulin suppression of apolipoprotein B in McArdle RH7777 cells involves increased sortilin 1 interaction and lysosomal targeting. Biochem Biophys Res Commun, 2013. 430(1): p. 66-71. [PMC free article: PMC3544973] [PubMed: 23159624]
23.: Chamoun, Z., et al., PNPLA3/adiponutrin functions in lipid droplet formation. Biol Cell, 2013. 105(5): p. 219-233. [PubMed: 23398201]
24.: Li, J.Z., et al., Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis. J Clin Invest, 2012. 122(11): p. 4130-44. [PMC free article: PMC3484461] [PubMed: 23023705]
25.: Pirazzi, C., et al., Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. J Hepatol, 2012. 57(6): p. 1276-82. [PubMed: 22878467]
26.: Fabbrini, E., et al., Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology, 2008. 134(2): p. 424-31. [PMC free article: PMC2705923] [PubMed: 18242210]
27.: Kozlitina, J., et al., Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet, 2014. 46(4): p. 352-6. [PMC free article: PMC3969786] [PubMed: 24531328]
28.: Dongiovanni, P., et al., Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology, 2015. 61(2): p. 506-14. [PubMed: 25251399]
29.: Liu, D.J., et al., Exome-wide association study of plasma lipids in >300,000 individuals. Nat Genet, 2017. 49(12): p. 1758-1766. [PMC free article: PMC5709146] [PubMed: 29083408]
30.: Chew, N.W.S., et al., The genetic interactions between non-alcoholic fatty liver disease and cardiovascular diseases. Front Genet, 2022. 13: p. 971484. [PMC free article: PMC9399730] [PubMed: 36035124]
31.: Schonfeld, G., Familial hypobetalipoproteinemia: a review. J Lipid Res, 2003. 44(5): p. 878-83. [PubMed: 12639976]
32.: Schonfeld, G., et al., Fatty liver in familial hypobetalipoproteinemia: triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis. J Lipid Res, 2003. 44(3): p. 470-8. [PubMed: 12562873]
33.: Welty, F.K., Hypobetalipoproteinemia and abetalipoproteinemia. Curr Opin Lipidol, 2014. 25(3): p. 161-8. [PMC free article: PMC4465983] [PubMed: 24751931]
34.: Tarugi, P. and A. Lonardo, Heterozygous familial hypobetalipoproteinemia associated with fatty liver. Am J Gastroenterol, 1997. 92(8): p. 1400-2. [PubMed: 9260828]
35.: Bonnefont-Rousselot, D., et al., Cryptogenic cirrhosis in a patient with familial hypocholesterolemia due to a new truncated form of apolipoprotein B. Eur J Gastroenterol Hepatol, 2009. 21(1): p. 104-8. [PubMed: 19060634]
36.: Lonardo, A., et al., Familial heterozygous hypobetalipoproteinemia, extrahepatic primary malignancy, and hepatocellular carcinoma. Dig Dis Sci, 1998. 43(11): p. 2489-92. [PubMed: 9824140]
37.: Caballero, F., et al., Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. J Hepatol, 2009. 50(4): p. 789-96. [PubMed: 19231010]
38.: Min, H.K., et al., Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab, 2012. 15(5): p. 665-74. [PMC free article: PMC3361911] [PubMed: 22560219]
39.: Yang, Y., et al., Suppression of ABCA1 by unsaturated fatty acids leads to lipid accumulation in HepG2 cells. Biochimie, 2010. 92(8): p. 958-63. [PubMed: 20385201]
40.: Van Rooyen, D.M., et al., Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology, 2011. 141(4): p. 1393-403, 1403 e1-5. [PMC free article: PMC3186822] [PubMed: 21703998]
41.: DeFilippis, A.P., et al., Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis, 2013. 227(2): p. 429-36. [PMC free article: PMC4049078] [PubMed: 23419204]
42.: Wu, K.T., et al., Nonalcoholic fatty liver disease severity is associated with the ratios of total cholesterol and triglycerides to high-density lipoprotein cholesterol. J Clin Lipidol, 2016. 10(2): p. 420-5 e1. [PubMed: 27055973]
43.: Lam, S.M., et al., Non-invasive lipid panel of MASLD fibrosis transition underscores the role of lipoprotein sulfatides in hepatic immunomodulation. Cell Metab, 2025. 37(1): p. 69-86 e7. [PubMed: 39500328]
44.: Li, J., et al., The relationship between the ratio of non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol (NHHR) and both MASLD and advanced liver fibrosis: evidence from NHANES 2017-2020. Front Nutr, 2025. 11: p. 1508106. [PMC free article: PMC11903283] [PubMed: 40084133]
45.: Corey, K.E., et al., Non-high-density lipoprotein cholesterol as a biomarker for nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol, 2012. 10(6): p. 651-6. [PMC free article: PMC3360815] [PubMed: 22330232]
46.: Sonmez, A., et al., Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease. J Clin Lipidol, 2015. 9(4): p. 576-82. [PubMed: 26228676]
47.: Corey, K.E., et al., NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levels. Aliment Pharmacol Ther, 2015. 41(3): p. 301-9. [PMC free article: PMC4424085] [PubMed: 25429853]
48.: Corey, K.E., et al., Nonalcoholic steatohepatitis is associated with an atherogenic lipoprotein subfraction profile. Lipids Health Dis, 2014. 13: p. 100. [PMC free article: PMC4074829] [PubMed: 24952382]
49.: Tsimikas, S., Lipoprotein(a) in the Year 2024: A Look Back and a Look Ahead. Arterioscler Thromb Vasc Biol, 2024. 44(7): p. 1485-1490. [PMC free article: PMC11210685] [PubMed: 38924439]
50.: Pelusi, S., et al., Interplay among lipoprotein(a), hepatic and vascular damage in individuals with metabolic dysfunction. Cardiovasc Diabetol, 2025. 24(1): p. 447. [PMC free article: PMC12659110] [PubMed: 41299661]
51.: Fan, H., et al., Lipoprotein (a) in the Full Spectrum of Metabolic Dysfunction-associated Steatotic Liver Disease: Evidence From Histologically and Genetically Characterized Cohorts. Clin Gastroenterol Hepatol, 2025. 23(8): p. 1356-1365 e5. [PubMed: 39672249]
52.: Xiao, T., et al., Association of Plasma Lipoprotein(a) With Major Adverse Cardiovascular Events in MASLD With or Without Advanced Liver Fibrosis. Liver Int, 2025. 45(8): p. e70208. [PubMed: 40607654]
53.: Yao, Z. and Y. Wang, Apolipoprotein C-III and hepatic triglyceride-rich lipoprotein production. Curr Opin Lipidol, 2012. 23(3): p. 206-212. [PubMed: 22510806]
54.: Sparks, C.E. and J.D. Sparks, Hepatic steatosis and VLDL hypersecretion. Curr Opin Lipidol, 2012. 23(4): p. 395-7. [PubMed: 22801389]
55.: Wang, H. and R.H. Eckel, Lipoprotein lipase: from gene to obesity. Am J Physiol Endocrinol Metab, 2009. 297(2): p. E271-88. [PubMed: 19318514]
56.: Shachter, N.S., Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol, 2001. 12(3): p. 297-304. [PubMed: 11353333]
57.: Gaudet, D., et al., Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med, 2014. 371(23): p. 2200-6. [PubMed: 25470695]
58.: Miksztowicz, V., et al., Hepatic lipase activity is increased in non-alcoholic fatty liver disease beyond insulin resistance. Diabetes Metab Res Rev, 2012. 28(6): p. 535-41. [PubMed: 22539458]
59.: Lambert, G., et al., The PCSK9 decade. J Lipid Res, 2012. 53(12): p. 2515-24. [PMC free article: PMC3494258] [PubMed: 22811413]
60.: Barrans, A., et al., Hepatic lipase induces the formation of pre-beta 1 high density lipoprotein (HDL) from triacylglycerol-rich HDL2. A study comparing liver perfusion to in vitro incubation with lipases. J Biol Chem, 1994. 269(15): p. 11572-7. [PubMed: 8157689]
61.: Horowitz, B.S., et al., Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol. J Clin Invest, 1993. 91(4): p. 1743-52. [PMC free article: PMC288154] [PubMed: 8473514]
62.: Zannis, V.I., A. Chroni, and M. Krieger, Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J Mol Med (Berl), 2006. 84(4): p. 276-94. [PubMed: 16501936]
63.: Nonomura, K., et al., Insulin down-regulates specific activity of ATP-binding cassette transporter A1 for high density lipoprotein biogenesis through its specific phosphorylation. Atherosclerosis, 2011. 216(2): p. 334-41. [PubMed: 21402379]
64.: Lucero, D., et al., Does non-alcoholic fatty liver impair alterations of plasma lipoproteins and associated factors in metabolic syndrome? Clin Chim Acta, 2011. 412(7-8): p. 587-92. [PubMed: 21159313]
65.: Ryan, M.C., et al., The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol, 2013. 59(1): p. 138-43. [PubMed: 23485520]
66.: Kirk, E., et al., Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology, 2009. 136(5): p. 1552-60. [PMC free article: PMC2677125] [PubMed: 19208352]
67.: Shai, I., et al., Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med, 2008. 359(3): p. 229-41. [PubMed: 18635428]
68.: Estruch, R., et al., Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med, 2013. 368(14): p. 1279-90. [PubMed: 23432189]
69.: Wood, P.D., et al., Increased exercise level and plasma lipoprotein concentrations: a one-year, randomized, controlled study in sedentary, middle-aged men. Metabolism, 1983. 32(1): p. 31-9. [PubMed: 6848894]
70.: Johnson, N.A., et al., Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology, 2009. 50(4): p. 1105-12. [PubMed: 19637289]
71.: Miranda, S., et al., Impact of semaglutide on lipid profiles in overweight and obese non-diabetic adults: A systematic review and meta-analysis of randomized controlled trials. Eur J Pharmacol, 2025. 1003: p. 177953. [PubMed: 40675357]
72.: Sanyal, A.J., et al., Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med, 2025. 392(21): p. 2089-2099. [PubMed: 40305708]
73.: Li, M., et al., Comparative effectiveness of GLP-1 receptor agonists and dual agonists in the treatment of patients with metabolic dysfunction associated steatohepatitis: a systematic review and meta-analysis. Front Endocrinol (Lausanne), 2025. 16: p. 1681965. [PMC free article: PMC12540095] [PubMed: 41133230]
74.: Harrison, S.A., et al., A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med, 2024. 390(6): p. 497-509. [PubMed: 38324483]
75.: Suvarna, R., S. Shetty, and J.M. Pappachan, Efficacy and safety of Resmetirom, a selective thyroid hormone receptor-beta agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis. Sci Rep, 2024. 14(1): p. 19790. [PMC free article: PMC11347689] [PubMed: 39187533]
76.: Harrison, S.A. and R. Taub, A Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis. Reply. N Engl J Med, 2024. 390(17): p. 1632-1633. [PubMed: 38692302]
77.: Athyros, V.G., et al., Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet, 2010. 376(9756): p. 1916-22. [PubMed: 21109302]
78.: Dongiovanni, P., et al., Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol, 2015. 63(3): p. 705-12. [PubMed: 25980762]
79.: Cohen, D.E., et al., An assessment of statin safety by hepatologists. Am J Cardiol, 2006. 97(8A): p. 77C-81C. [PubMed: 16581333]
80.: Chalasani, N., et al., Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology, 2004. 126(5): p. 1287-92. [PubMed: 15131789]
81.: Lewis, J.H., et al., Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology, 2007. 46(5): p. 1453-63. [PubMed: 17668878]
82.: Del Ben, M., et al., Under-prescription of statins in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis, 2017. 27(2): p. 161-167. [PubMed: 27914698]
83.: Wang, C., et al., n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. Am J Clin Nutr, 2006. 84(1): p. 5-17. [PubMed: 16825676]
84.: Cussons, A.J., et al., Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy. J Clin Endocrinol Metab, 2009. 94(10): p. 3842-8. [PubMed: 19622617]
85.: Spadaro, L., et al., Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis, 2008. 40(3): p. 194-9. [PubMed: 18054848]
86.: Yan, J.H., et al., Omega-3 polyunsaturated fatty acid supplementation and non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials. Medicine (Baltimore), 2018. 97(37): p. e12271. [PMC free article: PMC6155966] [PubMed: 30212963]
87.: Takeshita, Y., et al., The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. Diabetologia, 2014. 57(5): p. 878-90. [PubMed: 24407920]
88.: Loomba, R., et al., Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology, 2015. 61(4): p. 1239-50. [PMC free article: PMC4407930] [PubMed: 25482832]
89.: Grundy, S.M., et al., 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019. 139(25): p. e1082-e1143. [PMC free article: PMC7403606] [PubMed: 30586774]
90.: Mach, F., et al., 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J, 2020. 41(1): p. 111-188. [PubMed: 31504418]
91.: Gao, B., et al., Metabolic dysfunction and alcohol-associated liver disease (MetALD). eGastroenterology, 2025. 3(4): p. e100319. [PMC free article: PMC12742176] [PubMed: 41459093]
92.: Gao, B. and R. Bataller, Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology, 2011. 141(5): p. 1572-85. [PMC free article: PMC3214974] [PubMed: 21920463]
93.: O’Shea, R.S., et al., Alcoholic liver disease. Hepatology, 2010. 51(1): p. 307-28. [PubMed: 20034030]
94.: Wilfred de Alwis, N.M. and C.P. Day, Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. Semin Liver Dis, 2007. 27(1): p. 44-54. [PubMed: 17295176]
95.: Klop, B., A.T. do Rego, and M.C. Cabezas, Alcohol and plasma triglycerides. Curr Opin Lipidol, 2013. 24(4): p. 321-6. [PubMed: 23511381]
96.: Foerster, M., et al., Alcohol drinking and cardiovascular risk in a population with high mean alcohol consumption. Am J Cardiol, 2009. 103(3): p. 361-8. [PubMed: 19166690]
97.: Zhong, W., et al., Chronic alcohol exposure stimulates adipose tissue lipolysis in mice: role of reverse triglyceride transport in the pathogenesis of alcoholic steatosis. Am J Pathol, 2012. 180(3): p. 998-1007. [PMC free article: PMC3349880] [PubMed: 22234172]
98.: Baraona, E. and C.S. Lieber, Effects of ethanol on lipid metabolism. J Lipid Res, 1979. 20(3): p. 289-315. [PubMed: 87483]
99.: You, M., et al., Sirtuin 1 signaling and alcoholic fatty liver disease. Hepatobiliary Surg Nutr, 2015. 4(2): p. 88-100. [PMC free article: PMC4405418] [PubMed: 26005675]
100.: Czaja, M.J., et al., Functions of autophagy in normal and diseased liver. Autophagy, 2013. 9(8): p. 1131-58. [PMC free article: PMC3748187] [PubMed: 23774882]
101.: Mudrakova, E., R. Poledne, and J. Kovar, Postprandial triglyceridemia after single dose of alcohol in healthy young men. Nutr Metab Cardiovasc Dis, 2013. 23(3): p. 183-8. [PubMed: 21917433]
102.: Schneider, J., et al., Lipoprotein fractions, lipoprotein lipase and hepatic triglyceride lipase during short-term and long-term uptake of ethanol in healthy subjects. Atherosclerosis, 1985. 57(2-3): p. 281-91. [PubMed: 4084359]
103.: Ruixing, Y., et al., Interactions of the apolipoprotein C-III 3238C>G polymorphism and alcohol consumption on serum triglyceride levels. Lipids Health Dis, 2010. 9: p. 86. [PMC free article: PMC2929234] [PubMed: 20716347]
104.: Brinton, E.A., Effects of ethanol intake on lipoproteins. Curr Atheroscler Rep, 2012. 14(2): p. 108-14. [PubMed: 22350634]
105.: Hannuksela, M.L., M.K. Liisanantti, and M.J. Savolainen, Effect of alcohol on lipids and lipoproteins in relation to atherosclerosis. Crit Rev Clin Lab Sci, 2002. 39(3): p. 225-83. [PubMed: 12120782]
106.: Kuusisto, S.M., et al., The interplay between lipoprotein phenotypes, adiponectin, and alcohol consumption. Ann Med, 2012. 44(5): p. 513-22. [PubMed: 22077217]
107.: Stephen A. Harrison, J.M.S., Rebecca Taub, Dominic Labriola, Brandon Hill, Vlad Ratziu, SAT-263 Resmetirom treatment of a subgroup of patients with possible MetALD enrolled in MAESTRO-NASH, a phase 3 NASH/MASH serial liver biopsy stud. Journal of Hepatology, 2024. 80: p. S141-S142.
108.: Chuong, V., et al., The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight, 2023. 8(12). [PMC free article: PMC10371247] [PubMed: 37192005]
109.: Lavanchy, D., The global burden of hepatitis C. Liver Int, 2009. 29 Suppl 1: p. 74-81. [PubMed: 19207969]
110.: Andre, P., et al., Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol, 2002. 76(14): p. 6919-28. [PMC free article: PMC136313] [PubMed: 12072493]
111.: Lavie, M. and J. Dubuisson, Interplay between hepatitis C virus and lipid metabolism during virus entry and assembly. Biochimie, 2017. 141: p. 62-69. [PubMed: 28630011]
112.: Aizaki, H., et al., Critical role of virion-associated cholesterol and sphingolipid in hepatitis C virus infection. J Virol, 2008. 82(12): p. 5715-24. [PMC free article: PMC2395132] [PubMed: 18367533]
113.: Shimizu, Y., et al., Lipoprotein lipase and hepatic triglyceride lipase reduce the infectivity of hepatitis C virus (HCV) through their catalytic activities on HCV-associated lipoproteins. Virology, 2010. 407(1): p. 152-9. [PubMed: 20822787]
114.: Yamamoto, M., et al., Structural requirements of virion-associated cholesterol for infectivity, buoyant density and apolipoprotein association of hepatitis C virus. J Gen Virol, 2011. 92(Pt 9): p. 2082-2087. [PubMed: 21593275]
115.: Fauvelle, C., et al., Apolipoprotein E Mediates Evasion From Hepatitis C Virus Neutralizing Antibodies. Gastroenterology, 2016. 150(1): p. 206-217 e4. [PubMed: 26404951]
116.: Albecka, A., et al., Role of low-density lipoprotein receptor in the hepatitis C virus life cycle. Hepatology, 2012. 55(4): p. 998-1007. [PubMed: 22121002]
117.: Sainz, B., Jr., et al., Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med, 2012. 18(2): p. 281-5. [PMC free article: PMC3530957] [PubMed: 22231557]
118.: Wunschmann, S., et al., In vitro interaction between hepatitis C virus (HCV) envelope glycoprotein E2 and serum lipoproteins (LPs) results in enhanced cellular binding of both HCV E2 and LPs. J Infect Dis, 2006. 194(8): p. 1058-67. [PubMed: 16991080]
119.: Scarselli, E., et al., The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J, 2002. 21(19): p. 5017-25. [PMC free article: PMC129051] [PubMed: 12356718]
120.: Yamamoto, S., et al., Lipoprotein Receptors Redundantly Participate in Entry of Hepatitis C Virus. PLoS Pathog, 2016. 12(5): p. e1005610. [PMC free article: PMC4859476] [PubMed: 27152966]
121.: Ujino, S., et al., Hepatitis C virus utilizes VLDLR as a novel entry pathway. Proc Natl Acad Sci U S A, 2016. 113(1): p. 188-93. [PMC free article: PMC4711846] [PubMed: 26699506]
122.: Wang, C., et al., Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. Mol Cell, 2005. 18(4): p. 425-34. [PubMed: 15893726]
123.: Gastaminza, P., et al., Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J Virol, 2008. 82(5): p. 2120-9. [PMC free article: PMC2258938] [PubMed: 18077707]
124.: Corey, K.E., et al., Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology, 2009. 50(4): p. 1030-7. [PMC free article: PMC4330996] [PubMed: 19787818]
125.: Butt, A.A., et al., Changes in circulating lipids level over time after acquiring HCV infection: results from ERCHIVES. BMC Infect Dis, 2015. 15: p. 510. [PMC free article: PMC4642733] [PubMed: 26558512]
126.: Corey, K.E., et al., Acute hepatitis C infection lowers serum lipid levels. J Viral Hepat, 2011. 18(7): p. e366-71. [PMC free article: PMC3739431] [PubMed: 21692949]
127.: Butt, A.A., et al., Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis, 2009. 49(2): p. 225-32. [PMC free article: PMC3077953] [PubMed: 19508169]
128.: Roed, T., et al., Hepatitis C virus infection and risk of coronary artery disease: a systematic review of the literature. Clin Physiol Funct Imaging, 2012. 32(6): p. 421-30. [PubMed: 23031062]
129.: Butt, A.A., et al., Risk of Acute Myocardial Infarction Among Hepatitis C Virus (HCV)-Positive and HCV-Negative Men at Various Lipid Levels: Results From ERCHIVES. Clin Infect Dis, 2017. 65(4): p. 557-565. [PMC free article: PMC5850566] [PubMed: 28444148]
130.: Butt, A.A., et al., Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES. Hepatology, 2015. 62(2): p. 365-74. [PubMed: 25847403]
131.: Yang, Y.H., et al., Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection. J Hepatol, 2015. 63(5): p. 1111-7. [PubMed: 26196278]
132.: Zheng, Y.X., et al., The benefit of statins in chronic hepatitis C patients: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol, 2017. 29(7): p. 759-766. [PubMed: 28240613]
133.: Simon, T.G., et al., Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C. J Hepatol, 2015. 62(1): p. 18-23. [PMC free article: PMC4272642] [PubMed: 25135867]
134.: Simon, T.G., et al., Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES. Hepatology, 2016. 64(1): p. 47-57. [PMC free article: PMC4917438] [PubMed: 26891205]
135.: Gitto, S., et al., Worsening of Serum Lipid Profile after Direct Acting Antiviral Treatment. Ann Hepatol, 2018. 17(1): p. 64-75. [PubMed: 29311405]
136.: Hashimoto, S., et al., Rapid Increase in Serum Low-Density Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free Treatment. PLoS One, 2016. 11(9): p. e0163644. [PMC free article: PMC5040437] [PubMed: 27680885]
137.: Virseda-Berdices, A., et al., Long-term effects of HCV eradication on lipid profiles associated with MASLD among people with HIV with advanced fibrosis or cirrhosis. J Infect Public Health, 2025. 18(12): p. 102981. [PubMed: 41033169]
138.: Ott, J.J., et al., Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine, 2012. 30(12): p. 2212-9. [PubMed: 22273662]
139.: Organization, W.H., Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection, ed. H.a.S.P.H. Global HIV, Guidelines Review Committee. 2024.
140.: Yan, H., et al., Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide. J Virol, 2014. 88(6): p. 3273-84. [PMC free article: PMC3957944] [PubMed: 24390325]
141.: Lin, Y.L., et al., Cholesterol requirement of hepatitis B surface antigen (HBsAg) secretion. Virology, 2003. 314(1): p. 253-60. [PubMed: 14517078]
142.: Oehler, N., et al., Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism. Hepatology, 2014. 60(5): p. 1483-93. [PubMed: 24711282]
143.: Hajjou, M., et al., cDNA microarray analysis of HBV transgenic mouse liver identifies genes in lipid biosynthetic and growth control pathways affected by HBV. J Med Virol, 2005. 77(1): p. 57-65. [PubMed: 16032730]
144.: Hsu, C.S., et al., Impact of hepatitis B virus infection on metabolic profiles and modifying factors. J Viral Hepat, 2012. 19(2): p. e48-57. [PubMed: 22239526]
145.: Huang, C.Y., et al., Relationship between chronic hepatitis B and metabolic syndrome: A structural equation modeling approach. Obesity (Silver Spring), 2016. 24(2): p. 483-9. [PubMed: 26719030]
146.: Joo, E.J., et al., Chronic hepatitis B virus infection and risk of dyslipidaemia: A cohort study. J Viral Hepat, 2019. 26(1): p. 162-169. [PubMed: 30267602]
147.: Chen, E.Q., et al., Plasma Apolipoprotein A-V Predicts Long-term Survival in Chronic Hepatitis B Patients with Acute-on-Chronic Liver Failure. Sci Rep, 2017. 7: p. 45576. [PMC free article: PMC5372093] [PubMed: 28358016]
148.: Lefkowitch, J.H., et al., Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group. Gastroenterology, 1993. 104(2): p. 595-603. [PubMed: 8425703]
149.: Gordon, A., et al., Hepatic steatosis in chronic hepatitis B and C: predictors, distribution and effect on fibrosis. J Hepatol, 2005. 43(1): p. 38-44. [PubMed: 15876468]
150.: Huang, Y.W., et al., Statins Reduce the Risk of Cirrhosis and Its Decompensation in Chronic Hepatitis B Patients: A Nationwide Cohort Study. Am J Gastroenterol, 2016. 111(7): p. 976-85. [PubMed: 27166128]
151.: Kim, R.G., et al., Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol, 2017. 15(10): p. 1521-1530 e8. [PMC free article: PMC5605397] [PubMed: 28479502]
152.: Wong, J.C., et al., Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis. Aliment Pharmacol Ther, 2017. 46(10): p. 1001-1010. [PubMed: 28940673]
153.: Chang, F.M., et al., Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: A population-based study. Hepatology, 2017. 66(3): p. 896-907. [PubMed: 28318053]
154.: Hsiang, J.C., et al., Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis. J Hepatol, 2015. 63(5): p. 1190-7. [PubMed: 26208777]
155.: Cohen, D.E. and E.A. Fisher, Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease. Semin Liver Dis, 2013. 33(4): p. 380-8. [PMC free article: PMC3988578] [PubMed: 24222095]
156.: Jahn, C.E., et al., Lipoprotein abnormalities in primary biliary cirrhosis. Association with hepatic lipase inhibition as well as altered cholesterol esterification. Gastroenterology, 1985. 89(6): p. 1266-78. [PubMed: 4054519]
157.: Cohen, D.E., Hepatocellular transport and secretion of biliary lipids. Curr Opin Lipidol, 1999. 10(4): p. 295-302. [PubMed: 10482131]
158.: Hussain, I., Z. Ahmad, and A. Garg, Extreme hypercholesterolemia presenting with pseudohyponatremia - a case report and review of the literature. J Clin Lipidol, 2015. 9(2): p. 260-4. [PubMed: 25911084]
159.: Narayanan, S., Biochemistry and clinical relevance of lipoprotein X. Ann Clin Lab Sci, 1984. 14(5): p. 371-4. [PubMed: 6476782]
160.: Elferink, R.P., et al., Class III P-glycoproteins mediate the formation of lipoprotein X in the mouse. J Clin Invest, 1998. 102(9): p. 1749-57. [PMC free article: PMC509123] [PubMed: 9802889]
161.: Chang, P.Y., et al., Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation. J Lipid Res, 2004. 45(11): p. 2116-22. [PubMed: 15314101]
162.: Sniderman, A.D., et al., Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention. Eur Heart J, 2024. 45(27): p. 2410-2418. [PMC free article: PMC11242442] [PubMed: 38700053]
163.: Hao, J., et al., Serum Metabolomics Analysis Reveals a Distinct Metabolic Profile of Patients with Primary Biliary Cholangitis. Sci Rep, 2017. 7(1): p. 784. [PMC free article: PMC5429753] [PubMed: 28400566]
164.: Sorokin, A., J.L. Brown, and P.D. Thompson, Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review. Atherosclerosis, 2007. 194(2): p. 293-9. [PubMed: 17240380]
165.: Jorgensen, R.A., et al., Serum lipid and fat-soluble vitamin levels in primary sclerosing cholangitis. J Clin Gastroenterol, 1995. 20(3): p. 215-9. [PubMed: 7797830]
166.: Doycheva, I., et al., Asymptomatic primary biliary cirrhosis is not associated with increased frequency of cardiovascular disease. World J Hepatol, 2011. 3(4): p. 93-8. [PMC free article: PMC3098393] [PubMed: 21603031]
167.: Lindor, K.D., et al., Primary biliary cirrhosis. Hepatology, 2009. 50(1): p. 291-308. [PubMed: 19554543]
168.: Cash, W.J., et al., Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis. Liver Int, 2013. 33(8): p. 1166-74. [PubMed: 23672463]
169.: Ritzel, U., et al., Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers. J Hepatol, 2002. 36(4): p. 454-8. [PubMed: 11943414]
170.: Stojakovic, T., et al., Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment. Atherosclerosis, 2010. 209(1): p. 178-83. [PubMed: 19782361]
171.: Lindor, K.D., et al., ACG Clinical Guideline: Primary Sclerosing Cholangitis. Am J Gastroenterol, 2015. 110(5): p. 646-59; quiz 660. [PubMed: 25869391]
172.: Daniel R. Barros, B.G.B., Yogesh Patodia, Shaun Singer, Cheryl F. Rosen, Michael A. Seidman, Robert A. Hegele, Gary F. Lewis, Massive tissue deposition of cholesterol leading to multi-organ failure in cholestatic hypercholesterolemia. Journal of Clinical and Translational Endocrinology: Case Reports, 2025. 37.
173.: Cicognani, C., et al., Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis. Arch Intern Med, 1997. 157(7): p. 792-6. [PubMed: 9125012]
174.: Loria, P., et al., Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. Atherosclerosis, 2014. 232(1): p. 99-109. [PubMed: 24401223]
175.: Trieb, M., et al., Liver disease alters high-density lipoprotein composition, metabolism and function. Biochim Biophys Acta, 2016. 1861(7): p. 630-8. [PMC free article: PMC5542032] [PubMed: 27106140]
176.: Hwang, S.J., et al., Hypercholesterolaemia in patients with hepatocellular carcinoma. J Gastroenterol Hepatol, 1992. 7(5): p. 491-6. [PubMed: 1382658]
177.: Sohda, T., et al., 3-Hydroxyl-3-methylglutaryl-coenzyme A reductase is up regulated in hepatocellular carcinoma associated with paraneoplastic hypercholesterolemia. Med Mol Morphol, 2013. 46(4): p. 239-42. [PubMed: 23549978]
178.: Jiang, J., P. Nilsson-Ehle, and N. Xu, Influence of liver cancer on lipid and lipoprotein metabolism. Lipids Health Dis, 2006. 5: p. 4. [PMC free article: PMC1420303] [PubMed: 16515689]
179.: Erickson, S.K., et al., Regulation of cholesterol metabolism in a slow-growing hepatoma in vivo. Biochim Biophys Acta, 1988. 960(2): p. 131-8. [PubMed: 2835108]
180.: Feingold, K.R., et al., Altered activation state of hydroxymethylglutaryl-coenzyme A reductase in liver tumors. Arch Biochem Biophys, 1983. 226(1): p. 231-41. [PubMed: 6605722]
181.: Zein, N.N., et al., Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C, alcohol, or cholestatic disease. J Hepatol, 2000. 32(2): p. 209-17. [PubMed: 10707860]
182.: Habib, A., et al., High-density lipoprotein cholesterol as an indicator of liver function and prognosis in noncholestatic cirrhotics. Clin Gastroenterol Hepatol, 2005. 3(3): p. 286-91. [PubMed: 15765449]
183.: Kanwal, F., et al., GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. JAMA Intern Med, 2024. 184(11): p. 1314-1323. [PMC free article: PMC11406452] [PubMed: 39283612]

This electronic version has been made freely available under a Creative Commons (CC-BY-NC-ND) license. A copy of the license can be viewed at http://creativecommons.org/licenses/by-nc-nd/2.0/.

Bookshelf ID: NBK326742PMID: 26561702

Contents

< Prev Next >

PubReader
Print View
Cite this Page
Acuña M, Cohen DE. Lipid and Lipoprotein Metabolism in Liver Disease. [Updated 2026 Mar 6]. In: Feingold KR, Adler RA, Ahmed SF, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-.

In this Page

ABSTRACT
METABOLIC-DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE
ALCOHOLIC LIVER DISEASE
VIRAL HEPATITIS - C
VIRAL HEPATITIS - B
CHOLESTATIC DISEASES
CIRRHOSIS
ACKNOWLEDGEMENT
REFERENCES

LINKS TO WWW.ENDOTEXT.ORG

View this chapter in Endotext.org

Related information

PMC
PubMed Central citations
PubMed
Links to PubMed

Recent Activity

Clear Turn Off Turn On

Lipid and Lipoprotein Metabolism in Liver Disease - Endotext
Lipid and Lipoprotein Metabolism in Liver Disease - Endotext

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Bookshelf

Endotext [Internet].

Lipid and Lipoprotein Metabolism in Liver Disease

ABSTRACT

METABOLIC-DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE

Case Presentation

Introduction

Changes in Lipoprotein Metabolism and Clinical Manifestations

DEVELOPMENT OF STEATOSIS

Excess FFA Delivery to the Liver

Increased DNL

Insufficient Export of Hepatic Triglycerides

Hepatic Accumulation of Free Cholesterol

CHANGES IN LIPOPROTEINS

Table 1.

Insulin Resistance

INSULIN RESISTANCE INCREASES CIRCULATING LDL, VLDL, AND TRIGLYCERIDE LEVELS

INSULIN RESISTANCE DECREASES CIRCULATING HDL LEVELS

Management

OTHER LIPID-LOWERING MEDICATIONS

HMG-CoA Reductase Inhibitors

Omega-3 Fatty Acids

Cholesterol Absorption Inhibitors

LIPID TREATMENT GOALS

Return to Case

Table 2.

ALCOHOLIC LIVER DISEASE

Case Presentation

Introduction

Changes in Lipoprotein Metabolism and Clinical Manifestations

DEVELOPMENT OF STEATOSIS

Excess FFA Delivery to the Liver

Increased Denovo Lipid Synthesis

Impaired Oxidation and Degradation of Fatty Acids

Insufficient Export of Hepatic Triglycerides

HYPERTRIGLYCERIDEMIA

HDL LEVELS

LDL LEVELS

Table 3.

Management

Return to Case

Table 4.

VIRAL HEPATITIS - C

Case Presentation

Introduction

Changes in Lipoprotein Metabolism

Clinical Manifestations

Table 5.

Management

Return to Case

Table 6.

VIRAL HEPATITIS - B

Introduction

Lipoprotein Metabolism in Hepatitis B

Clinical Manifestations

Management

Table 7.

CHOLESTATIC DISEASES

Case Presentation

Introduction

Lipoprotein Metabolism in Cholestasis

Table 8.

Clinical Manifestations

Management

Return to Case

Table 9.

CIRRHOSIS

Introduction

Changes in Lipoprotein Metabolism and Clinical Manifestations

Table 10.

Management

ACKNOWLEDGEMENT

REFERENCES

Views

In this Page

LINKS TO WWW.ENDOTEXT.ORG

Related information

Similar articles in PubMed

Recent Activity